Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  • Fabio Efficace
  • Francesco Cottone
  • Kathrin Sommer
  • Jacobien Kieffer
  • Neil Aaronson
  • Peter Fayers
  • Mogens Groenvold
  • Giovanni Caocci
  • Francesco Lo Coco
  • Gianluca Gaidano
  • Pasquale Niscola
  • Michele Baccarani
  • Gianantonio Rosti
  • Adriano Venditti
  • Emanuele Angelucci
  • Paola Fazi
  • Marco Vignetti
  • Johannes Giesinger
Vis graf over relationer

OBJECTIVES: We investigated the validity of the recently developed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) summary score in patients with hematologic malignancies. Specifically, we evaluated the adequacy of a single-factor measurement model for the QLQ-C30, and its known-groups validity and responsiveness to change over time.

METHODS: We used confirmatory factor analysis to test the single-factor model of the QLQ-C30, using baseline QLQ-C30 data (N = 2134). The QLQ-C30 summary score was compared to the original QLQ-C30 scales using general (age, sex, Eastern Cooperative Oncology Group performance status, comorbidity) and disease-specific (red blood cell transfusion dependency) groups. Repeated measurements allowed us to investigate responsiveness to change in a subgroup of patients with acute myeloid leukemia.

RESULTS: The single-factor model of the QLQ-C30 exhibited adequate fit in patients with hematologic malignancies. Known-group comparisons generally supported the construct validity of the summary score when using more general grouping variables (sociodemographics, broad clinical parameters). Nevertheless, when groups were formed on the basis of disease-specific variables (eg, transfusion dependency), the summary score performed less well the some of the original, separate scales of the QLQ-C30.

CONCLUSION: Our findings provide support for the validity of the single-factor model of the EORTC QLQ-C30 in patients with hematologic malignancies. Specifically, the results suggest that the summary score can be used as an endpoint in this population when symptom- or other health domain-specific hypotheses are not available.

OriginalsprogEngelsk
TidsskriftValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Vol/bind22
Udgave nummer11
Sider (fra-til)1303-1310
Antal sider8
ISSN1098-3015
DOI
StatusUdgivet - nov. 2019

Bibliografisk note

Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

ID: 58891009